'the previous management achieved nothing but getting BOS to the brink of insolvency'
That's a bit harsh hardman. :\ Steinberg et al did create the company and the product (analogue library, IP from extensive industry trials). I do agree that commercialisation never got up and running. Maybe the directors could have done better there, or maybe the product needs more work. My gripe is they did not inform the market when trials failed. They just didn't say anything about it. Poor show. Much better to state the failures honestly.
In my earlier post I thought D’Sylva might favour Pharmaust and might direct some business from Biosignal their way. I looked through Pharmaust (PAA) announcements and found that D’Sylva was in fact no friend of theirs. It seems he, and Chimaera, tried to have Pharmaust wound up soon after he resigned on 3 August 2007. Dr. D'Sylva subsequently took up the position of Chief Executive Officer of Commonwealth Biotechnologies (NASDAQ Capital Market:CBTE) in January 2007 and served in that position until 23 Jan 2009. He remains a member of the Board of Directors until 2010.
Pharmaust had an interest in Commonwealth Biotechnologies until September 2008 when Pharmuast completed the sale of its majority shareholding to Venturepharm Laboratories Limited for a total of $3.5m.
So, now I am thinking it is more likely that D’Sylva or Empire Investments would involve Biosignal with Commonwealth Biotechnologies. Another Australian technology heading to the US?
All conjecture on my part of course – pondering while waiting for news from BOS, or ASIC, or Biotech Daily (via Thunder).
BOS Price at posting:
2.5¢ Sentiment: Hold Disclosure: Held
